Cadrenal Therapeutics to Conduct Partnering and Investor Meetings During the J.P. Morgan 44th Annual Healthcare Conference in San Francisco on January 12-15, 2026

Rhea-AI Summary

Cadrenal Therapeutics (Nasdaq: CVKD) said management, including CEO Quang X. Pham, will hold partnering and investor meetings during the J.P. Morgan 44th Annual Healthcare Conference in San Francisco on January 12-15, 2026. The company highlighted two 2025 acquisitions and stated its focus on the $40 billion anticoagulation market.

Cadrenal's pipeline items cited: VLX-1005 (phase 2 IV 12-LOX inhibitor; ODD and Fast Track for HIT), tecarfarin (phase 3-ready oral VKA; ODD and Fast Track for ESKD with AFib; ODD for LVAD in collaboration with Abbott), and frunexian (phase 2-ready IV FXIa inhibitor for acute care).

News Market Reaction – CVKD

-3.76%

8 alerts

-3.76% News Effect

+2.1% Peak Tracked

-19.2% Trough Tracked

-$693K Valuation Impact

$18M Market Cap

0.2x Rel. Volume

On the day this news was published, CVKD declined 3.76%, reflecting a moderate negative market reaction. Argus tracked a peak move of +2.1% during that session. Argus tracked a trough of -19.2% from its starting point during tracking. Our momentum scanner triggered 8 alerts that day, indicating moderate trading interest and price volatility. This price movement removed approximately $693K from the company's valuation, bringing the market cap to $18M at that time.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Anticoagulation market size: $40 billion VLX-1005 stage: Phase 2 Tecarfarin stage: Phase 3-ready +2 more

5 metrics

Anticoagulation market size $40 billion Global anticoagulation market targeted by Cadrenal

VLX-1005 stage Phase 2 First-in-class 12-LOX inhibitor for HIT

Tecarfarin stage Phase 3-ready Oral vitamin K antagonist for ESKD patients with AFib

Frunexian stage Phase 2-ready Acute parenteral Factor XIa inhibitor for surgical and CRRT settings

J.P. Morgan conference January 12–15, 2026 Planned partnering and investor meetings in San Francisco

Market Reality Check

Price: $5.73 Vol: Volume 319,324 is 4.81x t...

high vol

$5.73 Last Close

Volume Volume 319,324 is 4.81x the 20-day average of 66,455, indicating elevated trading activity before this conference-related update. high

Technical Price $8.25 is below the 200-day MA ($13.64) and sits closer to the 52-week low of $7.43 than the high of $22.90.

Peers on Argus

Peers showed mixed moves: TENX +5.18%, NEUP +1.04%, DARE -0.88%, while ALLR and ...

Peers showed mixed moves: TENX +5.18%, NEUP +1.04%, DARE -0.88%, while ALLR and NRSN were flat. This contrasts with CVKD’s -32.87% move, pointing to stock-specific dynamics rather than a broad biotech move.

Historical Context

5 past events · Latest: Dec 12 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Dec 12	Platform expansion	Positive	+0.0%	Detailed expansion of clinical platform and trial preparation activities.
Dec 12	Market opportunity	Positive	+0.0%	Positioned as multi-asset anticoagulation platform in a $40 billion market.
Dec 11	Asset acquisition	Positive	-1.0%	Acquisition of VLX-1005 with Orphan Drug and Fast Track designations.
Dec 01	Board appointment	Positive	-4.1%	Appointment of experienced cardiovascular and hematology drug developer.
Nov 10	Earnings update	Neutral	-3.2%	Q3 2025 financials with higher losses and added Factor XIa asset.

Pattern Detected

Recent news has generally been positive or strategic, yet price reactions were flat to negative, suggesting a pattern of weak or contrary trading responses to updates.

Recent Company History

Over the last few months, Cadrenal reported several pipeline-expanding moves and governance changes. On Nov 10, 2025, Q3 results highlighted higher operating expenses, larger losses, and liquidity concerns. Subsequent updates included appointing Dr. Lee Golden to the board on Dec 1, acquiring Phase 2 12‑LOX asset VLX‑1005 on Dec 11, and describing expansion into a $40 billion anticoagulation platform on Dec 12. Despite these developments, share reactions were flat to negative, framing today’s conference-meeting announcement against a backdrop of cautious market responses.

Market Pulse Summary

This announcement centers on Cadrenal’s plan to hold partnering and investor meetings at the J.P. Mo...

Analysis

This announcement centers on Cadrenal’s plan to hold partnering and investor meetings at the J.P. Morgan Healthcare Conference, spotlighting its three-asset anticoagulation pipeline, including VLX-1005, tecarfarin, and frunexian. In recent months the company added late-stage assets and expanded into a $40 billion market, but regulatory filings also highlighted higher losses and liquidity risks. Key metrics to monitor include trial initiations, partnering outcomes, and future financing decisions.

Key Terms

orphan drug designation, fast track designation, 12-lipoxygenase (12-lox), vitamin k antagonist (vka), +3 more

7 terms

orphan drug designation regulatory

"ODD and fast track designation for patients with heparin-induced thrombocytopenia"

Orphan drug designation is a special status given to medicines developed to treat rare diseases affecting only a small number of people. This status often provides benefits like faster approval processes and financial incentives, making it more attractive for companies to develop these drugs. For investors, it signals potential for exclusive market rights and reduced competition, which can impact the drug’s profitability.

fast track designation regulatory

"ODD and fast track designation for patients with heparin-induced thrombocytopenia"

A "fast track designation" is a process that speeds up the review and approval of a product or project, allowing it to reach the market or be completed more quickly than usual. For investors, it can signal that a product may become available sooner, potentially leading to earlier revenue or benefits, and indicating a priority status that might influence company performance and market opportunities.

12-lipoxygenase (12-lox) medical

"parenteral (intravenous) 12-Lipoxygenase (12-LOX) inhibitor designed to block key pathways"

An enzyme that acts like a tiny factory machine inside cells, converting certain fatty molecules into signaling compounds that influence inflammation, blood clotting, and cell growth. For investors, 12-lipoxygenase (12-LOX) matters because drugs or diagnostics that block or measure its activity can alter disease processes and create commercial opportunities or risks for clinical-stage biotech programs focused on conditions such as inflammatory disorders, cardiovascular disease, and some cancers.

vitamin k antagonist (vka) medical

"A phase 3-ready, oral Vitamin K antagonist (VKA) with a proven mechanism of action"

A vitamin K antagonist (VKA) is a type of blood‑thinning medicine that works by blocking vitamin K, a substance the body uses to make clotting factors; think of it as turning down a clotting “thermostat” to reduce the risk of dangerous clots. Investors care because VKAs drive markets for chronic-use drugs that require regular monitoring, have predictable but narrow safety margins, and face competitive and regulatory pressure from newer, easier-to-use alternatives.

left ventricular assist device (lvad) medical

"ODD for left ventricular assist device (LVAD) patients: collaboration with Abbott."

A left ventricular assist device (LVAD) is a small mechanical pump surgically implanted to help the heart’s left chamber push blood through the body when that chamber is too weak—think of it as a turbocharger for a failing engine. It matters to investors because LVADs represent high-cost, specialized medical products whose sales and profitability depend on device approvals, hospital adoption, insurance coverage, and ongoing upgrades, all of which drive company revenue and growth potential.

coronary artery bypass graft (cabg) medical

"For complex cardiac surgery (CABG) and continuous renal replacement therapy (CRRT) patients."

A coronary artery bypass graft (CABG) is a surgical procedure that restores blood flow to the heart by using a blood vessel taken from elsewhere in the body to create a new route around blocked coronary arteries — like rerouting traffic around a closed road. Investors care because CABG volumes, outcomes and costs influence hospital revenue, medical device and drug demand, insurance payouts, and regulatory or reimbursement decisions in the cardiovascular sector.

continuous renal replacement therapy (crrt) medical

"For complex cardiac surgery (CABG) and continuous renal replacement therapy (CRRT) patients."

Continuous renal replacement therapy (CRRT) is a slow, gentle form of dialysis used in intensive care to remove waste, excess fluid, and balance electrolytes from the blood around the clock when kidneys are failing. For investors, CRRT matters because it drives demand for specialized machines, consumable filters, training and hospital ICU time, and influences treatment costs and outcomes—factors that affect revenues and margins for medical device makers and healthcare providers.

AI-generated analysis. Not financial advice.

PONTE VEDRA, Fla., Dec. 17, 2025 (GLOBE NEWSWIRE) -- Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a biopharmaceutical company developing transformative therapeutics to overcome the limitations of current anticoagulation therapy, today announced that members of its management team, including Quang X. Pham, CEO, will hold partnering and investor meetings during the 44th Annual J.P. Morgan Healthcare Conference, to be held January 12-15, 2026 in San Francisco, CA.

“Attending the events surrounding the J.P. Morgan Healthcare Conference in San Francisco is a great opportunity for Cadrenal Therapeutics to engage directly with current and prospective partners and investors,” said Quang X. Pham, CEO of Cadrenal Therapeutics. “We look forward to productive meetings to discuss our strategies and the two acquisitions we’ve made in 2025 to advance our mission to develop novel, differentiated products that bridge critical gaps in current acute and chronic anticoagulation management for rare and high-risk patient populations.”

Cadrenal is focused on addressing gaps in the $40 billion anticoagulation market. The Company’s pipeline includes:

• VLX-1005
  • A phase 2, first-in-class parenteral (intravenous) 12-Lipoxygenase (12-LOX) inhibitor designed to block key pathways in immune-mediated platelet activation.
  • Blocks platelet activation and inhibits thrombus formation.
  • ODD and fast track designation for patients with heparin-induced thrombocytopenia (HIT).
• Tecarfarin        
  • A phase 3-ready, oral Vitamin K antagonist (VKA) with a proven mechanism of action (MoA) – same as warfarin.
  • Completely different – and desirable – metabolic pathway than warfarin.
  • Orphan drug designation (ODD) and fast track designation for end-stage kidney disease (ESKD) patients with atrial fibrillation (AFib).
  • ODD for left ventricular assist device (LVAD) patients: collaboration with Abbott.
• Frunexian
  • A phase 2-ready acute parenteral Factor XIa (FXIa) inhibitor.
  • Only parenteral FXIa with a fast-on / fast-off profile for acute care use.
  • For complex cardiac surgery (CABG) and continuous renal replacement therapy (CRRT) patients.
    

For partnering meetings, please contact the Company at press@cadrenal.com. For investor meetings, please get in touch with Lytham Partners at cvkd@lythampartners.com.

About Cadrenal Therapeutics, Inc.
Cadrenal Therapeutics, Inc. is developing differentiated products that bridge critical gaps in current acute and chronic anticoagulation management for rare and high-risk patient populations. It currently has three clinical-stage assets: VLX-1005, a first-in-class Phase 2 12-LOX Inhibitor for patients with HIT, tecarfarin, an oral vitamin K antagonist (VKA) for chronic use in patients with kidney dysfunction or left ventricular assist devices (LVADs), and frunexian, a parenteral small-molecule Factor XIa antagonist for use in acute hospital settings. For more information, visit https://www.cadrenal.com/ and connect with the Company on LinkedIn.

Safe Harbor

Any statements in this press release about future expectations, plans, and prospects, as well as any other statements regarding matters that are not historical facts, may constitute “forward-looking statements.” The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potentially,” “predict,” “project,” “should,” “target,” “will,” “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These statements include statements regarding the Company successfully developing transformative therapeutics to overcome the limitations of current anticoagulation therapy; members of the Company’s management team holding partnering and investor meetings during the 44th Annual J.P. Morgan Healthcare Conference, to be held January 12-15, 2026 in San Francisco, CA; discussing the Company’s strategies and the two acquisitions it made in 2025 at such meetings; developing novel, differentiated products that bridge critical gaps in current acute and chronic anticoagulation management for rare and high-risk patient populations; the Company addressing gaps in the $40 billion anticoagulation market. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including the ability to develop novel, differentiated products that bridge critical gaps in current acute and chronic anticoagulation management for rare and high-risk patient populations; the ability to successfully complete clinical trials on time and achieve desired results and benefits as expected; the ability to obtain regulatory approvals for commercialization of product candidates or to comply with ongoing regulatory requirements  and the other risk factors described in the Company’s Annual Report on Form 10-K for the year ended December 31, 2024, and the Company’s subsequent filings with the Securities and Exchange Commission, including subsequent periodic reports on Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. Any forward-looking statements contained in this press release speak only as of the date hereof and, except as required by federal securities laws, the Company specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events, or otherwise.

For more information, please contact:

Cadrenal Therapeutics:
Matthew Szot, CFO
press@cadrenal.com

Investors:
Lytham Partners, LLC
Robert Blum, Managing Partner
602-889-9700
CVKD@lythampartners.com

FAQ

When will Cadrenal Therapeutics (CVKD) hold meetings around the J.P. Morgan Healthcare Conference?

Management will hold partnering and investor meetings during January 12-15, 2026 in San Francisco.

How can investors request a meeting with Cadrenal (CVKD) at J.P. Morgan 2026?

Investors can contact Lytham Partners at cvkd@lythampartners.com to request a meeting.

What pipeline programs did Cadrenal (CVKD) highlight ahead of the January 2026 meetings?

The company highlighted VLX-1005 (phase 2 IV 12-LOX inhibitor), tecarfarin (phase 3-ready oral VKA), and frunexian (phase 2-ready IV FXIa inhibitor).

What designations does VLX-1005 have according to Cadrenal (CVKD)?

VLX-1005 has Orphan Drug Designation (ODD) and Fast Track designation for patients with heparin-induced thrombocytopenia (HIT).

What regulatory designations does tecarfarin hold for Cadrenal (CVKD)?

Tecarfarin has Orphan Drug Designation and Fast Track designation for end-stage kidney disease patients with atrial fibrillation, and an ODD for LVAD patients in collaboration with Abbott.

How can potential partners contact Cadrenal (CVKD) for partnering meetings at J.P. Morgan 2026?

Prospective partners can contact the company at press@cadrenal.com to arrange meetings.